PriceTargets.com logo

DaVita - DVA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $199.17
  • Forecasted Upside: 0.55%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$198.08 As of 05/13/2026 04:59 PM ET
▼ -2.462 (-1.23%)

This chart shows the closing price for DVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DaVita Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DVA

Analyst Price Target is $199.17
▲ +0.55% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for DaVita in the last 3 months. The average price target is $199.17, with a high forecast of $235.00 and a low forecast of $140.00. The average price target represents a 0.55% upside from the last price of $198.08.

This chart shows the closing price for DVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 8 investment analysts is to hold stock in DaVita. This rating has held steady since December 2025, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
11/14/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
2/12/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/13/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
5/13/2026

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/11/2026TD CowenBoost TargetHold ➝ Hold$144.00 ➝ $201.00
5/11/2026TD CowenBoost TargetHold ➝ Hold$144.00 ➝ $201.00
5/8/2026Truist FinancialBoost TargetHold ➝ Hold$158.00 ➝ $205.00
5/7/2026BarclaysBoost TargetEqual Weight ➝ Equal Weight$158.00 ➝ $194.00
5/7/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
5/7/2026UBS GroupBoost TargetBuy ➝ Buy$190.00 ➝ $235.00
5/6/2026Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$126.00 ➝ $220.00
4/6/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
2/5/2026Truist FinancialSet Target$158.00
2/4/2026UBS GroupBoost TargetBuy ➝ Buy$186.00 ➝ $190.00
2/4/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
2/3/2026TD CowenReiterated RatingHold ➝ Hold
2/3/2026BarclaysBoost TargetEqual Weight ➝ Equal Weight$143.00 ➝ $158.00
1/5/2026Truist FinancialLower TargetHold ➝ Hold$140.00 ➝ $128.00
12/29/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/22/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/15/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/15/2025UBS GroupReiterated RatingBuy ➝ Buy
12/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/28/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/25/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/19/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/13/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/3/2025TD CowenReiterated RatingHold ➝ Hold
11/3/2025TD CowenLower TargetHold ➝ Hold$154.00 ➝ $133.00
10/30/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$149.00 ➝ $143.00
10/30/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/14/2025Truist FinancialSet Target$140.00
10/9/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $149.00
10/8/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
9/27/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
9/10/2025Bank of AmericaLower TargetUnderperform ➝ Underperform$145.00 ➝ $140.00
8/8/2025Truist FinancialSet Target$148.00
8/7/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$169.00 ➝ $160.00
5/19/2025Truist FinancialLower TargetHold ➝ Hold$170.00 ➝ $164.00
2/21/2025Sanford C. BernsteinSet Target$184.00
2/18/2025TD CowenReiterated RatingHold ➝ Hold
2/18/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00
10/31/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$150.00 ➝ $164.00
10/7/2024Truist FinancialBoost TargetHold ➝ Hold$165.00 ➝ $175.00
8/20/2024Truist FinancialBoost TargetHold ➝ Hold$150.00 ➝ $165.00
8/8/2024UBS GroupBoost TargetBuy ➝ Buy$169.00 ➝ $175.00
8/7/2024Bank of AmericaBoost TargetUnderperform ➝ Underperform$139.00 ➝ $145.00
7/24/2024TD CowenBoost TargetHold ➝ Hold$139.00 ➝ $150.00
5/15/2024Truist FinancialBoost TargetHold ➝ Hold$135.00 ➝ $150.00
5/6/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$133.00 ➝ $150.00
3/6/2024BarclaysInitiated CoverageEqual Weight$133.00
2/20/2024Truist FinancialBoost TargetHold ➝ Hold$130.00 ➝ $135.00
2/14/2024UBS GroupBoost TargetBuy ➝ Buy$113.00 ➝ $134.00
2/14/2024Truist FinancialBoost TargetHold ➝ Hold$120.00 ➝ $130.00
11/17/2023UBS GroupLower TargetBuy ➝ Buy$142.00 ➝ $113.00
10/11/2023Truist FinancialLower TargetHold ➝ Hold$115.00 ➝ $104.00
8/7/2023UBS GroupUpgradeNeutral ➝ Buy$100.00 ➝ $142.00
7/13/2023Truist FinancialBoost TargetHold$100.00 ➝ $115.00
5/15/2023Sanford C. BernsteinBoost Target$88.00 ➝ $100.00
5/9/2023Truist FinancialBoost Target$90.00 ➝ $100.00
5/9/2023Deutsche Bank AktiengesellschaftBoost Target$85.00 ➝ $113.00
5/9/2023UBS GroupBoost Target$91.00 ➝ $100.00
5/9/2023Bank of AmericaBoost Target$86.00 ➝ $96.00
3/7/2023Sanford C. BernsteinInitiated CoverageMarket Perform
2/23/2023Deutsche Bank AktiengesellschaftBoost Target$72.00 ➝ $85.00
2/23/2023Truist FinancialBoost TargetHold$84.00 ➝ $90.00
2/23/2023TD CowenBoost TargetOutperform$76.00 ➝ $90.00
11/1/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$97.00 ➝ $72.00
10/31/2022Truist FinancialLower TargetHold$90.00 ➝ $75.00
10/31/2022BarclaysLower TargetEqual Weight$103.00 ➝ $81.00
10/31/2022UBS GroupDowngradeBuy ➝ Neutral$117.00 ➝ $74.00
8/19/2022UBS GroupBoost TargetNeutral ➝ Buy$106.00 ➝ $117.00
8/9/2022TD CowenLower Target$95.00
8/4/2022BarclaysLower TargetEqual Weight$128.00 ➝ $103.00
8/2/2022Deutsche Bank AktiengesellschaftLower TargetBuy$150.00 ➝ $97.00
6/22/2022Truist FinancialLower TargetHold$110.00 ➝ $90.00
6/21/2022Bank of AmericaLower TargetUnderperform$110.00 ➝ $90.00
5/6/2022Truist FinancialLower Target$125.00 ➝ $110.00
1/5/2022Truist FinancialBoost TargetHold ➝ Hold$114.00 ➝ $125.00
11/17/2021Deutsche Bank AktiengesellschaftLower TargetPositive ➝ Buy$164.00 ➝ $150.00
10/29/2021Royal Bank Of CanadaLower TargetSector Perform$113.00 ➝ $111.00
10/29/2021Deutsche Bank AktiengesellschaftLower TargetBuy$207.00 ➝ $164.00
10/13/2021Truist FinancialLower TargetHold$145.00 ➝ $125.00
9/9/2021TD CowenInitiated CoverageMarket Perform$145.00
8/12/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$135.00 ➝ $146.00
8/4/2021William BlairReiterated RatingMarket Perform
7/19/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$150.00 ➝ $207.00
(Data available from 5/13/2021 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2025
  • 5 very positive mentions
  • 14 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/14/2025
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/13/2026
  • 8 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2026
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/14/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/13/2026
  • 26 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/13/2026

Current Sentiment

  • 26 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DaVita logo
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Read More

Today's Range

Now: $198.08
Low: $196.88
High: $201.93

50 Day Range

MA: $156.68
Low: $144.41
High: $200.22

52 Week Range

Now: $198.08
Low: $101.00
High: $202.69

Volume

638,504 shs

Average Volume

965,488 shs

Market Capitalization

$12.72 billion

P/E Ratio

18.37

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of DaVita?

The following sell-side analysts have issued reports on DaVita in the last twelve months: Bank of America Corporation, Barclays PLC, Deutsche Bank Aktiengesellschaft, TD Cowen, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for DVA.

What is the current price target for DaVita?

0 Wall Street analysts have set twelve-month price targets for DaVita in the last year. Their average twelve-month price target is $199.17, suggesting a possible upside of 0.5%. UBS Group AG has the highest price target set, predicting DVA will reach $235.00 in the next twelve months. Bank of America Corporation has the lowest price target set, forecasting a price of $140.00 for DaVita in the next year.
View the latest price targets for DVA.

What is the current consensus analyst rating for DaVita?

DaVita currently has 1 sell rating, 4 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DVA, but not buy more shares or sell existing shares.
View the latest ratings for DVA.

What other companies compete with DaVita?

Other companies that are similar to DaVita include Align Technology, DexCom, HealthEquity, Merit Medical Systems and Cardinal Health. Learn More about companies similar to DaVita.

How do I contact DaVita's investor relations team?

DaVita's physical mailing address is 2000 16TH STREET, DENVER CO, 80202. The company's listed phone number is (720) 631-2100 and its investor relations email address is [email protected]. The official website for DaVita is www.davita.com. Learn More about contacing DaVita investor relations.